


What Must Change If Future Evidence Pricing And Access Challenges Are To Be Successfully Overcome?




Teale C¹, Tolley R², Morrison S², Ballantyne A²

¹ TealeHealth, Chesterfield, UK ² Ipsos, London, UK



Introduction and objective

- To identify future evidence pricing and access challenges, and solutions for overcoming these, highlighting the systemic, stakeholder, and organisational changes required.



Methodology



- Using the ISPOR top 10 HEOR trends 2022/3 as catalyst, a 2-cycle delphi approach based on broad expert opinion (n=41) was used to determine the key evidence pricing and access challenges over the period 2023-30.
- Scope covered complete lifecycle pathway, evolution of digital health and genomic insight, and consideration of value attribution. Cluster analysis was used to structure the output.

For each cluster, solutions to overcoming the challenges were identified.



Results

- The majority of the 30 specific challenges were applicable to most therapy areas.
- The 30 challenges involved multiple stakeholders and capability requirements.



- The research indicated that the challenges can rarely be solved in isolation, in a single company or departmental silo, or based on single data sources.
- The largest cluster (7/30) comprised personalisation challenges (digital and molecular diagnostics / biomarkers linked to therapeutic).

Collaboration and access to multiple 'integratable' data sources will be critical success factors.

These challenges must be addressed if the promises of improved economic, clinical and humanistic outcomes are to be delivered^{1 & 2}.

Three key challenges need to be addressed for digital health to be successful

The first challenge: speed of evolution

Technology is evolving faster than the regulatory, behavioural, healthcare funding, and health technology assessment (HTA) systems that are required for successful implementation.

The second challenge: evidence

There are various challenges to evidence development in this environment, including:

- Relevance, robustness, and rigor
- Difficulty and cost of evidence development
- Timeliness of evidence delivery
- Continued validity of evidence in a rapidly evolving environment
- Measurement and attribution of co-dependent value between developers of the different disease management components.


The third challenge: value

Value will be attributed and assessed in different ways:

- Value contribution of 3 different elements: monitoring, intervention & prediction (the MIP paradigm)
- Value segmentation based on 3 outcome types: economic, clinical & humanistic
- Value perception based on 3 stakeholder groups: patient, payer & physician
- Value attribution, informing value-based reimbursement allocation

Eight barriers to molecular diagnostics and five to therapy use will need to be removed for biomarker driven healthcare to be successful

- Barriers to molecular diagnostic use may include:**
 - Funding
 - Access to and availability of testing
 - Testing methods and process: difficulty of obtaining sample, complexity, and turnaround time
 - Test performance: will the test be (or be perceived to be) insufficiently accurate or ambiguous?
 - Population selected for testing: will the population tested be as broad as the drug's indication?
 - Physician's adoption of the test proposition
 - Patient demand for testing, and willingness to be tested
 - Conversion rate: will physicians prescribe other drugs despite a "positive" test result?
- Barriers to therapy use may include:**
 - Affordability, access and availability of drugs, diagnostic testing, reimbursement, and of data/evidence
 - Timing: delays in updating treatment guidelines, delays in Health Technology Assessments and implementation, and time lag in adopting technology
 - Preference: influenced by context, personal experience, and outcomes of earlier treatment(s)
 - Policy & priorities
 - Power: Physician vs. payer, HTA vs. medical society, and treatment guideline perspectives differing from patients perspectives.




Conclusions

- To overcome challenges, **changes** will be required in 5 areas⁴:
 - Systemic changes (Information Technology (IT) Systems, Regulatory and Health Technology Assessment Systems, Coding Payment and Funding Systems, Ethical and Legal Systems)
 - Stakeholder changes (Physicians, Patients, Payers, Manufacturers)
 - Organisational changes (Commercial, Evidence Development (R&D and HEOR), Market Access, Market / Business insight)
 - Strategic collaboration between manufacturers and data providers to access data
 - Integration of data from multiple sources (Prescription data, Electronic medical records (EMRs), Health resource utilisation (HRU), Claims data, Real-time / wearable data, Social media data)




Solutions

Evidence, pricing and access will need to be re-engineered to address four factors




Fundamental changes will be required to overcome the evidence availability, accessibility, and acceptability challenge

New methodologies will need to be applied to help decision-makers understand drivers of change



Non-comparative data, plus modelling solutions, will increasingly be required



Financial engineering will be needed to address the challenges of gene, and other therapies, with high price density

Gene therapy presents specific challenges...

- Cost and affordability
- Funding flows
- Uncertainty: absence of data around long-term benefit
- Value definition

...cost is the biggest concern...

The cost of these therapies can be extremely expensive. Budget impact could be amplified depending on the size of the patient population. A further challenge is the timing of the cost. The fact is that all or most of the costs are up-front, not borne over time, as with chronic treatment


...and uncertainty around long-term benefit...

The pathway to approval of gene therapies (especially if expedited) may yield shorter-term data on efficacy than is needed to prove long-term benefit. This results in great uncertainty around how long the therapeutic benefit will last and whether a single dose will be sufficient to provide a lifetime cure. This impacts payer willingness to pay and ability to pay

...leading to problems of defining value

Payers may have to incorporate measures of value to patients, the healthcare system, and society in the standard value assessments. Additional metrics include: disease severity, age of onset, lifetime burden of the illness and informal care elements, such as returning to work or study, increases in productivity and reductions in burden of care

New payer-types will emerge, and funding flows will need to change to relieve financial pressures



Any one, or combination, of these models have the potential to incentivise payers to invest in a gene therapy that may produce a better health outcome and lower cost over time, as opposed to paying for a competing product that is administered, with higher long-term costs – or even with a larger one-time/upfront costs for a curative therapy.



Contact

Chris Teale
Chris@tealehealth.com

Andrew Ballantyne
Andrew.Ballantyne@Ipsos.com

Richard Tolley
Richard.Tolley@Ipsos.com



References

- The Monitor Intervene Predict Value Framework, Teale, ISPOR Value and Outcomes Spotlight, January 2023
- The Power of Holistic Insights: An Ipsos POV, Teale, Franceschetti, Levent, Duncan, November 2022
- EPA Congress 2021: Pricing & Access Challenges in the absence of data. Teale et al
- 30 Major Future Challenges in Evidence, Pricing & Access and How to Overcome Them. An Ipsos POV. May 2023